Exclusive Summary

• Backed by both US FDA and EU EMA GMP certifications, enabling expedited regulatory registration and launch in global markets.
• A highly complex long-acting injectable with significant technical barriers, resulting in very few generic competitors and an excellent blue-ocean market landscape.
• A $1B+ global blockbuster, firmly recommended by NCCN guidelines as a first-line treatment for Acromegaly and GEP-NETs with rigid demand.
• Offers reliable, high-quality supply with significant cost advantages over the expensive reference drug, ensuring highly attractive profit margins for distributors.